176
Participants
Start Date
January 31, 2006
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
GI-4000
Heat-killed yeast cell transfected with target ras mutation.
Gemcitabine
Chemotherapy
State University of NY at Stony Brook, Stony Brook
Georgetown University Medical Center / Lombardi Cancer Center, Washington D.C.
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
University of Alabama at Birmingham, Birmingham
Ohio State University, Columbus
Froedtert Multi-Disciplinary Cancer Clinic, Milwaukee
Minnesota Oncology Hematology, PA, Minneapolis
Rush University Medical School, Chicago
Washington University, St Louis
Texas Oncology, PA, Dallas
The Texas Cancer Center Dallas Southwest, Dallas
Tyler Cancer Center, Tyler
Baylor College of Medicine, Houston
South Texas Oncology & Hematology, San Antonio
UCLA Medical Center, Los Angeles
Tower Cancer Research Foundation, Beverly Hills
University of California San Diego, La Jolla
Seattle Cancer Care Alliance, Seattle
G B Pan Hospital & Maulana Azad Medical College, New Delhi
Indo American Cancer Hospital and Research Centre, Hyderabad
Nizam's Institute of Medical Sciences, Panjagutta, Hyderaba
KMC Hospital, Mangalore
Lifeline Multispecialty Hospital, Perungudi, Chennai
Sri Ramchandra Medical College & Research Institute, Ponur, Chennai
PSG Hospitals, Peelamedu, Coimbatore
Lake Shore Hospital & Research Centre, Nettoor, Cochin
Regional Cancer Centre, Trivandrum
Govt Medical Colleg & Hospital, Nagpur
Lead Sponsor
GlobeImmune
INDUSTRY